SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rhoades, K. L. Articles by Zhang, D.-E. Search for Related Content PubMed PubMed Citation Articles by Rhoades, K. L. Articles by Zhang, D.-E. Related Collections Hematopoiesis and Stem Cells Neoplasia Oncogenes and Tumor Suppressors Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2000, Vol. 96, No. 6, pp. 2108-2115 HEMATOPOIESIS Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model Kristina L. Rhoades, Christopher J. Hetherington, Nari Harakawa, Donald A. Yergeau, Liming Zhou, Li-Qin Liu, Marie-Terese Little, Daniel G. Tenen, and Dong-Er Zhang From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; and Department of Medicine, Harvard Medical School, Boston, MA. As reported previously, AML1-ETO knock-in mice were generated to investigate the role of AML1-ETO in leukemogenesis and to mimic the progression of t(8;21) leukemia. These knock-in mice died in midgestation because of hemorrhaging in the central nervous system and a block of definitive hematopoiesis during embryogenesis. Therefore, they are not a good model system for the development of acute myeloid leukemia. Therefore, mice were generated in which the expression of AML1-ETO is under the control of a tetracycline-inducible system. Multiple lines of transgenic mice have been produced with the AML1-ETO complementary DNA controlled by a tetracycline-responsive element. In the absence of the antibiotic tetracycline, AML1-ETO is strongly expressed in the bone marrow of AML1-ETO and tet-controlled transcriptional activator double-positive transgenic mice. Furthermore, the addition of tetracycline reduces AML1-ETO expression in double-positive mice to nondetectable levels. Throughout the normal murine lifespan of 24 months, mice expressing AML1-ETO have not developed leukemia. In spite of this, abnormal maturation and proliferation of progenitor cells have been observed from these animals. These results demonstrate that AML1-ETO has a very restricted capacity to transform cells. Either the introduction of additional genetic changes or the expression of AML1-ETO at a particular stage of hematopoietic cell differentiation will be necessary to develop a model for studying the pathogenesis of t(8;21). © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Akagi, L.-Y. Shih, S. Ogawa, J. Gerss, S. R. Moore, R. Schreck, N. Kawamata, D.-C. Liang, M. Sanada, Y. Nannya, et al. Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells Haematologica, September 1, 2009; 94(9): 1301 - 1306. [Abstract] [Full Text] [PDF] D. Osman, V. Gobert, F. Ponthan, O. Heidenreich, M. Haenlin, and L. Waltzer A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO PNAS, July 21, 2009; 106(29): 12043 - 12048. [Abstract] [Full Text] [PDF] L. Roudaia, M. D. Cheney, E. Manuylova, W. Chen, M. Morrow, S. Park, C.-T. Lee, P. Kaur, O. Williams, J. H. Bushweller, et al. CBF{beta} is critical for AML1-ETO and TEL-AML1 activity Blood, March 26, 2009; 113(13): 3070 - 3079. [Abstract] [Full Text] [PDF] M. Yan, E.-Y. Ahn, S. W. Hiebert, and D.-E. Zhang RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis Blood, January 22, 2009; 113(4): 883 - 886. [Abstract] [Full Text] [PDF] E.-Y. Ahn, M. Yan, O. A. Malakhova, M.-C. Lo, A. Boyapati, H. B. Ommen, R. Hines, P. Hokland, and D.-E. Zhang Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis PNAS, November 4, 2008; 105(44): 17103 - 17108. [Abstract] [Full Text] [PDF] N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura AML1 mutations induced MDS and MDS/AML in a mouse BMT model Blood, April 15, 2008; 111(8): 4297 - 4308. [Abstract] [Full Text] [PDF] F. Dayyani, J. Wang, J.-R. J. Yeh, E.-Y. Ahn, E. Tobey, D.-E. Zhang, I. D. Bernstein, R. T. Peterson, and D. A. Sweetser Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival Blood, April 15, 2008; 111(8): 4338 - 4347. [Abstract] [Full Text] [PDF] L. F. Peterson, A. Boyapati, E.-Y. Ahn, J. R. Biggs, A. J. Okumura, M.-C. Lo, M. Yan, and D.-E. Zhang Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts Blood, August 1, 2007; 110(3): 799 - 805. [Abstract] [Full Text] [PDF] L. F. Peterson, M. Yan, and D.-E. Zhang The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO Blood, May 15, 2007; 109(10): 4392 - 4398. [Abstract] [Full Text] [PDF] A. Boyapati, M. Yan, L. F. Peterson, J. R. Biggs, M. M. Le Beau, and D.-E. Zhang A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy Blood, May 1, 2007; 109(9): 3963 - 3971. [Abstract] [Full Text] [PDF] E. Bockamp, C. Antunes, M. Maringer, R. Heck, K. Presser, S. Beilke, S. Ohngemach, R. Alt, M. Cross, R. Sprengel, et al. Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells Blood, September 1, 2006; 108(5): 1533 - 1541. [Abstract] [Full Text] [PDF] S. Nishida, N. Hosen, T. Shirakata, K. Kanato, M. Yanagihara, S.-i. Nakatsuka, Y. Hoshida, T. Nakazawa, Y. Harada, N. Tatsumi, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1 Blood, April 15, 2006; 107(8): 3303 - 3312. [Abstract] [Full Text] [PDF] L. F. Peterson, A. Boyapati, V. Ranganathan, A. Iwama, D. G. Tenen, S. Tsai, and D.-E. Zhang The Hematopoietic Transcription Factor AML1 (RUNX1) Is Negatively Regulated by the Cell Cycle Protein Cyclin D3 Mol. Cell. Biol., December 1, 2005; 25(23): 10205 - 10219. [Abstract] [Full Text] [PDF] K. Maki, T. Yamagata, T. Asai, I. Yamazaki, H. Oda, H. Hirai, and K. Mitani Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos Blood, September 15, 2005; 106(6): 2147 - 2155. [Abstract] [Full Text] [PDF] H. G. Nguyen, G. Yu, M. Makitalo, D. Yang, H.-X. Xie, M. R. Jones, and K. Ravid Conditional overexpression of transgenes in megakaryocytes and platelets in vivo Blood, September 1, 2005; 106(5): 1559 - 1564. [Abstract] [Full Text] [PDF] J. Wildonger and R. S. Mann The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor Development, May 15, 2005; 132(10): 2263 - 2272. [Abstract] [Full Text] [PDF] J. C. Mulloy, V. Jankovic, M. Wunderlich, R. Delwel, J. Cammenga, O. Krejci, H. Zhao, P. J. M. Valk, B. Lowenberg, and S. D. Nimer AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion PNAS, March 15, 2005; 102(11): 4016 - 4021. [Abstract] [Full Text] [PDF] Y.-Y. Wang, G.-B. Zhou, T. Yin, B. Chen, J.-Y. Shi, W.-X. Liang, X.-L. Jin, J.-H. You, G. Yang, Z.-X. Shen, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec PNAS, January 25, 2005; 102(4): 1104 - 1109. [Abstract] [Full Text] [PDF] J. L. Hess and B. A. Hug Fusion-protein truncation provides new insights into leukemogenesis PNAS, December 7, 2004; 101(49): 16985 - 16986. [Full Text] [PDF] M. Yan, S. A. Burel, L. F. Peterson, E. Kanbe, H. Iwasaki, A. Boyapati, R. Hines, K. Akashi, and D.-E. Zhang From the Cover: Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development PNAS, December 7, 2004; 101(49): 17186 - 17191. [Abstract] [Full Text] [PDF] T. S. Fenske, G. Pengue, V. Mathews, P. T. Hanson, S. E. Hamm, N. Riaz, and T. A. Graubert Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice PNAS, October 19, 2004; 101(42): 15184 - 15189. [Abstract] [Full Text] [PDF] J. Zhang, M. Kalkum, S. Yamamura, B. T. Chait, and R. G. Roeder E Protein Silencing by the Leukemogenic AML1-ETO Fusion Protein Science, August 27, 2004; 305(5688): 1286 - 1289. [Abstract] [Full Text] [PDF] S. Tsuzuki, M. Seto, M. Greaves, and T. Enver Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice PNAS, June 1, 2004; 101(22): 8443 - 8448. [Abstract] [Full Text] [PDF] D. L. McCormick and R. Kavet Animal Models for the Study of Childhood Leukemia: Considerations for Model Identification and Optimization to Identify Potential Risk Factors International Journal of Toxicology, May 1, 2004; 23(3): 149 - 161. [Abstract] [Full Text] [PDF] X. Zheng, T. Beissert, N. Kukoc-Zivojnov, E. Puccetti, J. Altschmied, C. Strolz, S. Boehrer, H. Gul, O. Schneider, O. G. Ottmann, et al. {gamma}-Catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells Blood, May 1, 2004; 103(9): 3535 - 3543. [Abstract] [Full Text] [PDF] F. Bernardin-Fried, T. Kummalue, S. Leijen, M. I. Collector, K. Ravid, and A. D. Friedman AML1/RUNX1 Increases During G1 to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression J. Biol. Chem., April 9, 2004; 279(15): 15678 - 15687. [Abstract] [Full Text] [PDF] M. Schwieger, J. Lohler, M. Fischer, U. Herwig, D. G. Tenen, and C. Stocking A dominant-negative mutant of C/EBP{alpha}, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse Blood, April 1, 2004; 103(7): 2744 - 2752. [Abstract] [Full Text] [PDF] P. Klausen, M. D. Bjerregaard, N. Borregaard, and J. B. Cowland End-stage differentiation of neutrophil granulocytes in vivo is accompanied by up-regulation of p27kip1 and down-regulation of CDK2, CDK4, and CDK6 J. Leukoc. Biol., March 1, 2004; 75(3): 569 - 578. [Abstract] [Full Text] [PDF] J. C. Mulloy, J. Cammenga, F. J. Berguido, K. Wu, P. Zhou, R. L. Comenzo, S. Jhanwar, M. A. S. Moore, and S. D. Nimer Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element Blood, December 15, 2003; 102(13): 4369 - 4376. [Abstract] [Full Text] [PDF] J. L. Grisolano, J. O'Neal, J. Cain, and M. H. Tomasson An activated receptor tyrosine kinase, TEL/PDGF{beta}R, cooperates with AML1/ETO to induce acute myeloid leukemia in mice PNAS, August 5, 2003; 100(16): 9506 - 9511. [Abstract] [Full Text] [PDF] Q. Xu, S.-E. Simpson, T. J. Scialla, A. Bagg, and M. Carroll Survival of acute myeloid leukemia cells requires PI3 kinase activation Blood, August 1, 2003; 102(3): 972 - 980. [Abstract] [Full Text] [PDF] O. Heidenreich, J. Krauter, H. Riehle, P. Hadwiger, M. John, G. Heil, H.-P. Vornlocher, and A. Nordheim AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells Blood, April 15, 2003; 101(8): 3157 - 3163. [Abstract] [Full Text] [PDF] J. Cammenga, J. C. Mulloy, F. J. Berguido, D. MacGrogan, A. Viale, and S. D. Nimer Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells Blood, March 15, 2003; 101(6): 2206 - 2214. [Abstract] [Full Text] [PDF] M. L. Kalev-Zylinska, J. A. Horsfield, M. V. C. Flores, J. H. Postlethwait, M. R. Vitas, A. M. Baas, P. S. Crosier, and K. E. Crosier Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis Development, March 6, 2003; 129(8): 2015 - 2030. [Abstract] [Full Text] [PDF] O. A. Malakhova, M. Yan, M. P. Malakhov, Y. Yuan, K. J. Ritchie, K. I. Kim, L. F. Peterson, K. Shuai, and D.-E. Zhang Protein ISGylation modulates the JAK-STAT signaling pathway Genes & Dev., February 15, 2003; 17(4): 455 - 460. [Abstract] [Full Text] [PDF] A. Tonks, L. Pearn, A. J. Tonks, L. Pearce, T. Hoy, S. Phillips, J. Fisher, J. R. Downing, A. K. Burnett, and R. L. Darley The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells Blood, January 15, 2003; 101(2): 624 - 632. [Abstract] [Full Text] [PDF] R. K. Vangala, M. S. Heiss-Neumann, J. S. Rangatia, S. M. Singh, C. Schoch, D. G. Tenen, W. Hiddemann, and G. Behre The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia Blood, January 1, 2003; 101(1): 270 - 277. [Abstract] [Full Text] [PDF] E. Puccetti, D. Obradovic, T. Beissert, A. Bianchini, B. Washburn, F. Chiaradonna, S. Boehrer, D. Hoelzer, O. G. Ottmann, P. G. Pelicci, et al. AML-associated Translocation Products Block Vitamin D3-induced Differentiation by Sequestering the Vitamin D3 Receptor Cancer Res., December 1, 2002; 62(23): 7050 - 7058. [Abstract] [Full Text] [PDF] P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF] K. Barseguian, B. Lutterbach, S. W. Hiebert, J. Nickerson, J. B. Lian, J. L. Stein, A. J. van Wijnen, and G. S. Stein Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins PNAS, November 26, 2002; 99(24): 15434 - 15439. [Abstract] [Full Text] [PDF] M. Schwieger, J. Lohler, J. Friel, M. Scheller, I. Horak, and C. Stocking AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency J. Exp. Med., November 4, 2002; 196(9): 1227 - 1240. [Abstract] [Full Text] [PDF] J. Basecke, L. Cepek, C. Mannhalter, J. Krauter, S. Hildenhagen, G. Brittinger, L. Trumper, and F. Griesinger Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia Blood, August 28, 2002; 100(6): 2267 - 2267. [Full Text] [PDF] C. G. de Guzman, A. J. Warren, Z. Zhang, L. Gartland, P. Erickson, H. Drabkin, S. W. Hiebert, and C. A. Klug Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation Mol. Cell. Biol., August 1, 2002; 22(15): 5506 - 5517. [Abstract] [Full Text] [PDF] H. Mori, S. M. Colman, Z. Xiao, A. M. Ford, L. E. Healy, C. Donaldson, J. M. Hows, C. Navarrete, and M. Greaves Chromosome translocations and covert leukemic clones are generated during normal fetal development PNAS, June 11, 2002; 99(12): 8242 - 8247. [Abstract] [Full Text] [PDF] S. Nguyen, T. Leblanc, P. Fenaux, F. Witz, D. Blaise, A. Pigneux, X. Thomas, F. Rigal-Huguet, B. Lioure, A. Auvrignon, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup Blood, May 15, 2002; 99(10): 3517 - 3523. [Abstract] [Full Text] [PDF] B. A. Hug, S. Y. D. Lee, E. L. Kinsler, J. Zhang, and M. A. Lazar Cooperative Function of Aml1-ETO Corepressor Recruitment Domains in the Expansion of Primary Bone Marrow Cells Cancer Res., May 1, 2002; 62(10): 2906 - 2912. [Abstract] [Full Text] [PDF] J. Pedersen-Bjergaard, M. K. Andersen, D. H. Christiansen, and C. Nerlov Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia Blood, March 15, 2002; 99(6): 1909 - 1912. [Abstract] [Full Text] [PDF] J. C. Mulloy, J. Cammenga, K. L. MacKenzie, F. J. Berguido, M. A. S. Moore, and S. D. Nimer The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells Blood, January 1, 2002; 99(1): 15 - 23. [Abstract] [Full Text] [PDF] L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model Blood, January 1, 2002; 99(1): 310 - 318. [Abstract] [Full Text] [PDF] Y. Yuan, L. Zhou, T. Miyamoto, H. Iwasaki, N. Harakawa, C. J. Hetherington, S. A. Burel, E. Lagasse, I. L. Weissman, K. Akashi, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations PNAS, August 28, 2001; 98(18): 10398 - 10403. [Abstract] [Full Text] [PDF] S. A. Burel, N. Harakawa, L. Zhou, T. Pabst, D. G. Tenen, and D.-E. Zhang Dichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation Mol. Cell. Biol., August 15, 2001; 21(16): 5577 - 5590. [Abstract] [Full Text] [PDF] D. A. Sweetser, C.-S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, et al. Loss of heterozygosity in childhood de novo acute myelogenous leukemia Blood, August 15, 2001; 98(4): 1188 - 1194. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020